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ABSTRACT
Diabetic cardiomyopathy is a distinct primary disease process, independent of coronary artery
disease, which leads to heart failure in diabetic patients. Epidemiological and clinical trial
data have conﬁrmed the greater incidence and prevalence of heart failure in diabetes. Novel
echocardiographic and MR (magnetic resonance) techniques have enabled a more accurate means
of phenotyping diabetic cardiomyopathy. Experimental models of diabetes have provided a range of
novel molecular targets for this condition, but none have been substantiated in humans. Similarly,
although ultrastructural pathology of the microvessels and cardiomyocytes is well described
in animal models, studies in humans are small and limited to light microscopy. With regard to
treatment, recent data with thiazoledinediones has generated much controversy in terms of the
cardiac safety of both these and other drugs currently in use and under development. Clinical
trials are urgently required to establish the efﬁcacy of currently available agents for heart failure,
as well as novel therapies in patients speciﬁcally with diabetic cardiomyopathy.
INTRODUCTION
The link between HF (heart failure) and diabetes is well
documented, but the existence of diabetic cardiomyo-
pathy as a distinct clinical entity continues to be the sub-
ject of debate. In 1881, Leyden commented that HF was
a “frequent and noteworthy complication of diabetes
mellitus” [1] and Mayer stated that “heart disease in
diabetes can be traced to an abnormality in metabolism”
[2]. In 1972, Rubler et al. [3] coined the term ‘diabetic
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cardiomyopathy’ after performing post mortem studies
in diabetic patients with cardiac failure, having
excluded alcohol, hypertension, and coronary and
structural heart disease as possible aetiologies. Diabetic
cardiomyopathy has since been the subject of much
research and controversy, with evolving debate on the
best management strategy for this entity. By deﬁnition,
diabetic cardiomyopathy is a distinct primary disease
process which develops secondary to a metabolic insult,
resulting in structural and functional abnormalities of the
myocardium leading to HF. We have comprehensively
updated our previous review [4], taking into account the
most recent developments in basic and translational re-
search, together with an overview of the latest diagnostic
and therapeutic approaches to diabetic cardiomyopathy.
EPIDEMIOLOGY
The prevalence of HF in the general population ranges
from 1 to 4%, but in diabetic patients it is 12% [5], rising
to 22% in those over the age of 64 years [6]. Up to a third
of all patients admitted to hospital with HF have diabetes
[7]. Furthermore, diabetes has a prevalence of 30% in
patients with cardiac failure [8] and may be up to four
times as prevalent in patients with newly diagnosed HF
[9].Diabetesisalsoapowerfulpredictorofcardiovascular
morbidityandmortality,andisanindependentriskfactor
for death in patients with established HF [10]. Diabetic
patients are also more likely than non-diabetic patients
to develop HF following MI (myocardial infarction),
despite comparable infarct sizes [11]. The Framingham
Heart Study reported a 2.4-fold increase in the incidence
of HF in diabetic men and a 5.1-fold increase in diabetic
women, when compared with age-matched controls [12].
This association was independent of age, hypertension,
dyslipidaemia, obesity and coronary heart disease. Other
large population-based studies have yielded similar
results [13]. The CHS (Cardiovascular Health Study)
of patients aged over 65 years showed diabetes to be
associated with an increase in incident HF [14] and the
SHS (Strong Heart Study) demonstrated associations
between diabetes and higher LVM [LV (left ventricular)
mass] and wall thickness, increased arterial stiffness and
systolic dysfunction, compared with matched controls
[15]. More recently, the MESA (Multi-Ethnic Study
of Atherosclerosis) study used cardiac MR (magnetic
resonance) to report inter-racial differences in LVM,
LV volumes and LV function among diabetic patients
[16].
Cross-sectional studies have consistently reported a
high prevalence of HF in diabetic populations [6].
Alarmingly, one study observed 12% of Type 2 diabetic
patients with HF at entry, with an annual incidence
of 3.3% [17]. In a similar study over 43 months, the
incidence of HF was vastly higher in diabetic (39%)
compared with non-diabetic (23%) patients, with an RR
(relative risk) of 1.3 for developing HF [18]. The UKPDS
(UK Prospective Diabetes Study) found an increased
prevalence of HF in Type 2 diabetic patients, which
correlated with higher HbA1c (glycated haemoglobin)
levels[19].Indeed,forevery1%increaseinHbA1c,there
isan8%increasedriskofdevelopingHF[20].Arecently
published study has demonstrated an increased risk of
HF in diabetic patients with retinopathy, supporting the
concept of a microvascular aetiology in diabetic heart
disease [21]. Sub-group analysis of the MESA cohort also
revealedanassociationbetweenretinalarteriolarnarrow-
ing and LV remodelling, lending weight to this argument
[22].
It is not surprising, therefore, that diabetic patients are
over-represented in large HF trial populations; such as
SOLVD (Studies of Left Ventricular Dysfunction) [23]
(diabetic patients represent 26%), ATLAS (Assessment
of Treatment with Lisinopril and Survival) [24] (diabetic
patients represent 19%), V-HeFT (Vasodilator-Heart
Failure Trial) [25] (diabetic patients represent 20%) and
RESOLVD (Randomized Evaluation of Strategies for
Left Ventricular Dysfunction) [26] (diabetic patients rep-
resent27%).Inadditiontoovertclinicaldiabetes,insulin
resistance and the metabolic syndrome are also inde-
pendent predictors of HF [27,28]. Inﬂammatory markers
such as CRP (C-reactive protein) and IL (interleukin)-
6, as well as microalbuminuria, which are frequently
elevated in individuals with the metabolic syndrome, are
independently associated with incident HF [29]. This
suggeststhatcardiomyopathymayoccurin‘pre-diabetic’
individuals.Inaretrospectivestudyofacohortofpatients
with a primary diagnosis of HF, metabolic syndrome was
present in 68% of patients, but, interestingly, mortality
was lower in those with (44%) compared with those
without (58%) the metabolic syndrome [30].
RISK FACTORS ASSOCIATED WITH THE
DEVELOPMENT OF HF IN DIABETES
Hyperglycaemia
In the UKPDS, although poor glycaemic control was
associated with an increased risk of HF [19], intensive
glycaemic control did not reduce the risk of incident
HF. A more recent study of Type 2 diabetic patients
has, however, demonstrated an improvement in long-
axisfunction(systolicstrainrate)andreductionsinLVM,
which were associated with improvements in HbA1c and
fructosaminelevels[31].Thesechangeswereindependent
of any BP (blood pressure)-lowering effects. In addition,
therewasanimprovementindiastolicfunctionduringthe
ﬁrst 3 months of follow up, which returned to baseline at
12 months. Another study by Marwick and co-workers
[32] has reported a similar association between lower
C   The Authors Journal compilation C   2009 Biochemical Society
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Diabetic cardiomyopathy 743
HbA1c and improved systolic strain. In a 10 year follow-
up of the UKPDS, despite an early loss of glycaemic dif-
ference between groups receiving intensive and conven-
tional treatment, an emergent risk reduction for MI and
death from any cause was observed following intensive
glucose-lowering [33], although no data was reported for
HF. However, conﬂicting data has been generated from
tworecentlargerandomizedinterventiontrials.TheAD-
VANCE (Action in Diabetes and Vascular Disease) trial
compared intensive with standard glycaemic control and
showedanon-signiﬁcantreductioninincidentHF,butan
increased all-cause mortality at 3.5 years [34]. Increased
mortality in the ACCORD (Action to Control Cardio-
vascular Risk in Diabetes) trial led to the discontinuation
of the intensive glycaemic control arm of the study [35].
Hypertension
Hypertension is independently associated with LVH
(LV hypertrophy), diastolic dysfunction, HF and
cardiovascularrisk[4].IntheUKPDS,lowerBP,achieved
by either a β-blocker or ACEI [ACE (angiotensin-
converting enzyme) inhibitor], was associated with a
reduced risk of incident HF compared with less intensive
BP control. However, again it is interesting to note that
both during and in the recent 10 year follow-up of the
UKPDS, BP reduction did not demonstrate the ‘legacy
effect’, i.e. there was no risk reduction during or after
the trial for MI or death from any cause [36].
STRUCTURAL FEATURES OF DIABETIC
CARDIOMYOPATHY AND THEIR FUNCTIONAL
RELEVANCE
LVH
LVH is a powerful predictor of cardiovascular risk. The
Framingham Heart Study demonstrated an increased
relative risk of developing cardiovascular disease
for each 50 g/m2 increment in LVMI (LVM index;
RR 1.49 compared with 1.57, males compared with
females) [37]. Furthermore, LVH predicts prognosis in
high-risk patient groups, such as those with coronary
heart disease [38], HF [39], diabetes [40], renal failure
[41], hypertension [42], obesity and previous MI
[43]. Pharmacological regression of LVH is associ-
ated with a reduction in cardiovascular risk [44].
The RENAAL [Reduction of Endpoints in NIDDM
(non-insulin-dependent diabetes mellitus) with the
Angiotensin II Antagonist Losartan] study in patients
with diabetic nephropathy, found that LVH was a
signiﬁcant risk factor for the primary endpoints of
end-stage renal failure, death or cardiovascular events
[45]. Several studies have since reported an association
between diabetes and LVH [46]. The SHS reported
increased LVM and LV wall thickness in both diabetic
men and women, and these differences remained
statistically signiﬁcant in multivariate analyses after
adjusting for confounding factors [47]. Similar ﬁndings
werereportedintheCHS[48]andMESA[49],asdetailed
above. Interestingly, a sub-study of the MESA cohort
reported an independent association between retinal
arteriolar narrowing and LV remodelling, which was
stronger in diabetic patients, suggesting microvascular
involvement [22]. The Framingham Heart Study also
reported increased LVM across all categories of glucose
dysmetabolism. A recent study of Japanese Type 2
diabetic patients reported an association between insulin
resistance,arterialstiffnessandLVMI[usingcardiacMRI
(MRimaging)][47],andthishasbeensupportedbyalarge
population-based study in Sweden, which demonstrated
associations between metabolic syndrome, insulin
resistance and increased LVM and LV wall thickness
[48].
Diastolic dysfunction
Diastolic function of the left ventricle is determined by
its passive elastic properties, coupled with the process of
active relaxation. Diastolic dysfunction is characterized
by impairment of relaxation and passive ﬁlling of the
left ventricle [49], and diastolic HF is said to exist when
diastolic dysfunction is associated with an elevated
end diastolic pressure, clinical features of HF and a
normal EF (ejection fraction). This may be better termed
HFNEF (HF with a normal EF), since there is emerging
evidenceofsubtleabnormalitiesinregionalandlong-axis
systolic function in some of these patients.
Functional abnormalities occur as a result of structural
remodelling (concentric LVH) and result in normal or
near-normal end diastolic volume, elevated LVM to
volume and elevated wall thickness to chamber radius
relationships respectively. Indeed, the development of
diastolic dysfunction has been associated with only mod-
est increases in LVM [47]. In diabetic cardiomyopathy
with reduced LVEF, myocardial collagen deposition and
AGEs (advanced glycosylation end-products) are the
primary pathological processes responsible for reduced
elasticity of the myocardium, whereas increased car-
diomyocyte resting tension may be the predominant
cause in those cases with preserved LVEF [50]. LVH
and geometric remodelling on the other hand, cause
an increase in passive stiffness and impaired relaxation.
Consequently, the LV pressure–volume curve is shifted
upward and leftward, chamber compliance is reduced,
diastolic ﬁlling is altered with an elevation of the end dia-
stolic pressure, and HF ensues.
Diastolic dysfunction is a common ﬁnding in
otherwise healthy and asymptomatic diabetic patients
and is thought to be the earliest detectable functional
abnormality in diabetic cardiomyopathy [51]. In a study
of normotensive, asymptomatic Type 2 diabetic patients
with good glycaemic control, 47% were found to have
diastolic dysfunction [52]. Other studies using more
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sensitive diagnostic methods have reported that as many
as 75% of diabetic patients demonstrate abnormalities
of diastolic function [53].
Systolic dysfunction
Advances in TDI (tissue Doppler imaging) have allowed
for measurement of sensitive indices of regional and
long-axis function of both the left and right ventricles
[54]. Indeed, long-axis function is emerging as a superior
prognostic indicator to EF, especially in patients with
HFNEF [55]. Using these sensitive methods, several
studies have demonstrated subtle abnormalities in
systolic function in patients with a diagnosis of diastolic
dysfunction [56–58]. This has led some to question
whether diastolic dysfunction exists in isolation at all
[59], whereas others have questioned the relevance of
these subtle systolic abnormalities in the context of dia-
stolic dysfunction [60]. The longitudinal ﬁbres respons-
ible for long-axis contraction lie in the sub-endocardium
and are particularly susceptible to the effects of ﬁbrosis,
ischaemia or hypertrophy. In diabetic patients with
HFNEF, long-axis systolic dysfunction is associated
with a compensatory increase in radial thickening and
mass, thus preserving LVEF [61]. The preservation of EF
is directly related to the presence of LVH and the effect
of increased muscle mass. Patients with HFNEF have
signiﬁcantly higher LVMI, lower LVED (left ventricular
end-diastole) volume index, higher LVMI/LVED volume
index ratio than patients with dilated left ventricles and a
low EF. Although most studies to date have concentrated
on LV function, the importance of RV (right ventricular)
function should not be overlooked; RVEF has previously
been shown to be an independent predictor of poor
outcome [62]. Furthermore, RV diastolic dysfunction
has been reported in asymptomatic patients with Type 1
diabetes [63].
DIAGNOSTIC METHODS
Although no single diagnostic test for diabetic cardio-
myopathy exists, using different imaging modalities it
is possible to detect the phenotypic cardiac features of
this condition. Currently used diagnostic methods in
clinical practice include echocardiography, cardiac MR
and cardiac biomarkers such as NT-BNP [N-terminal
pro-BNP (brain natriuretic peptide)].
Echocardiography
Echocardiography is an excellent non-invasive and prac-
tical imaging tool for deﬁning cardiac structure and
functionandallows‘real-time’visualizationofthecardiac
cycle.Quantitativeandqualitativeassessmentoftheheart
can be made with regard to LV geometry, regional wall
motion,and systolicand diastolicfunction, in additionto
valvular anatomy and function. Two-dimensional echo-
cardiography has traditionally been the method of choice
in detecting and quantifying LVH, and has been valid-
ated in the research and clinical setting. The main
limitation of two-dimensional echocardiography is for
patients with major distortions of LV geometry. As a
result, most existing data from studies of LVH and LVM
have been derived using standard two-dimensional and
M-mode echocardiography. Although considered to be
the ‘gold standard’ for assessing LV diastolic function,
cardiac catheterization is not essential to diagnose dia-
stolic dysfunction [63]. Pulsed-wave Doppler echocar-
diography is therefore the most practical and commonly
used method for current assessment of diastolic function.
A detailed and comprehensive diastolic study is vital in
diabetic patients and should include the measurement of
transmitralandpulmonaryvenousﬂow/velocities,aswell
as left atrial volume [64]. LVEF is the most commonly
used index of LV systolic function and is derived
echocardiographically. Despite being well established in
clinical practice, it is important to be aware that it can be
inﬂuenced by alterations in preload and afterload.
LVEF is not as sensitive for assessing contractile func-
tioninpatientswithHFNEFandTDIechocardiography
ismorecapableofdetectingsubtleregionalabnormalities
in LV function. TDI allows non-invasive assessment of
myocardial strain and has been shown to identify global
andregionalabnormalitiesinmyocardialproperties,with
a high level of temporal resolution. TDI differs from
conventional Doppler in that it utilizes a ﬁlter which
eliminates high velocity and low amplitude signals reﬂec-
ted from blood cells, thereby allowing low velocity, high
amplitude tissue signals to be analysed. Myocardial strain
and strain rate are dimensionless indices of changes in
lengththatreﬂecttissuedeformation[65].Theseparamet-
ers have been extensively validated in a range of different
disease states, including acute ischaemic syndromes [66],
and have been found to be indicative of preclinical
myocardial disease in patients with Type 2 diabetes
[57].
Cardiac MRI
Cardiac MRI, owing to its superior accuracy and
reproducibility, is the ‘gold standard’ for measuring LVM
[67]. Currently however, its use is mainly limited to
research, due to costs, time constraints and the expertise
required for assessment.
Cardiac biomarkers
BNP is a cardiac hormone secreted in response to
ventricular volume and pressure overload. Although it
is both sensitive and speciﬁc for congestive HF, it can-
notreliablydistinguishbetweensystolicanddiastolicHF,
whichlimitsitsdiagnosticuseindiabeticcardiomyopathy
[56,68].
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Figure 1 Summary of interactions between the myocardial and vascular changes present in diabetic hearts and their
contribution to diabetic cardiomyopathy and heart failure
Ang II R1, AT1; IGF-1, insulin-like growth factor-1.
MOLECULAR BASIS
Several putative factors have been considered important
in the genesis of the functional and structural alterations
which lead to the development and progression of dia-
betic cardiomyopathy (Figure 1). The molecular basis of
thisconditionhasbeenestablishedprimarilyfromstudies
in experimental models of diabetic cardiomyopathy [69],
with few studies carried out in humans [4].
Hyperglycaemia
Several studies, most notably the Diabetes Control
and Complications Trial/Epidemiology of Diabetes
Interventions and Complications study, have shown that
hyperglycaemia is indeed a mediator of cardiovascular
risk in Type 1 diabetes and that intensive diabetic therapy
reduces cardiac outcomes via an impact on accelerated
atherosclerosis, cardiac autonomic neuropathy and pos-
sibly cardiomyopathy [70]. In a population-based cohort
study of 746 subjects stratiﬁed into normal and abnormal
glucose tolerance and overt Type 2 diabetes, there was
an independent increase in risk of developing systolic
(2-fold) and diastolic (2.4-fold) dysfunction in patients
withType2diabetes,withdiastolicdysfunctionapparent
even in those with impaired glucose tolerance [71].
Hyperglycaemia mediates its damaging effects through a
series of secondary transducers which will be considered.
ROS (reactive oxygen species) and NO
Oxidative stress occurs when the production of ROS
outweighs their degradation by antioxidant defences
and the elevation of ROS leads to cellular damage by
oxidation, disruption of vascular homoeostasis through
interference with NO and, most recently, by modulation
of detrimental intracellular signalling pathways. ROS
have been implicated in all stages of the development
of HF, from cardiac hypertrophy to ﬁbrosis, contractile
dysfunction and failure [71]. Diabetic hearts exhibit a
similar picture to that of failing hearts, with numerous
studies reporting increased production of ROS in a
variety of animal models of diabetes [71]. Increased
ROS causes cardiac dysfunction by direct damage to
proteins and DNA {inducing PARP [poly(ADP-ribose)
polymerase]whichwillbeconsideredlater},aswellasby
promoting apoptosis. Furthermore, overexpression [72]
orpharmacologicaladministration[73]oftheantioxidant
metallothionein in rodent models of diabetes has been
shown to ameliorate diabetic cardiomyopathy. Similar
results have been reproduced using other antioxidants in
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both Type 1 and Type 2 rodent models of diabetes [74].
NADPH oxidase enzymes are a source of ROS and are
involved in redox signalling by acting as catalysts for
electron transfer from NADPH to molecular oxygen,
resulting in the generation of free radicals [75]. They
comprise multisubunit complexes, which range from
NOX1toNOX5[75].Throughinteractionwithavariety
of transcription factors, redox signalling inﬂuences the
expression of growth-related genes and in-turn effects
contractilefunction[76].NADPHoxidaseisincreasedin
both failing [77] and diabetic [78] rodent hearts and this
relationship is believed to be causal. In diabetic animals,
up-regulation of NADPH oxidase correlates with
cardiac hypertrophy and up-regulation of pro-ﬁbrotic
genes such as pro-collagen III; changes which can be
ameliorated using the antioxidant Tempol [79]. ROS also
react directly with NO to form peroxynitrite species,
thereby inactivating the vasodilatory effect of NO,
whichisintegraltovascularhomoeostasisandendothelial
function.Incombinationwithotherpathologywithinthe
endothelium [80], these changes provide an explanation
for accelerated endothelial dysfunction seen in predia-
beticmice[81].Interestingly,antioxidantssuchasvitamin
Carecapableofrestoringendothelialfunctioninpatients
with HF [82]. Reductions in the release of NO from
endothelial cells, as a consequence of ROS, have also
been shown to affect ventricular relaxation in LVH [83].
Thus experimental data suggest that regimes targeting
reduction of ROS or increasing antioxidant activity
potentially represent novel therapeutic modalities for
diabetic cardiomyopathy. However, clinical studies
to date have been unable to translate these results to
the clinic, with several large randomized trials failing
to report a beneﬁt of antioxidants on cardiovascular
outcome in high-risk individuals [84]. The outcome of
suchtrialsinpatientswithdiabeticcardiomyopathyhow-
ever, has not been investigated.
PARP
PARP enzymes are overactivated in diabetes [85] as a
reparative response to ROS-induced oxidative damage
to DNA (see above). PARP inhibits GAPDH (gly-
ceraldehyde-3-phosphate dehydrogenase), which leads
to accumulation of glycolytic intermediates, which in-
turn activate a series of transducers which inﬂict tissue
damage via AGE formation and PKC (protein kinase
C) activation [85]. PARP also promotes cardiac damage
by activating NF-κB (nuclear factor κB) [87] and
inducing overexpression of the vasoconstrictor ET
(endothelin)-1 and its receptors [88]. Both hyperhexo-
saemia and hyperglycaemia have been shown to induce
oxidative stress and up-regulate extracellular matrix and
cardiomyocyte hypertrophy and these changes were
effectively abolished in PARP-1 knockout (Parp−/−)
mice and in rats treated with the PARP inhibitor
ABA (3-aminobenzamide) [89]. PARP-driven cardiac
hypertrophy and ﬁbrosis appears to be mediated in
hearts and cardiomyocytes via up-regulation of the tran-
scriptional co-activator p300 [89]. Thus the widespread
damage caused by PARP potentially creates a unique
opportunity for blocking multiple sources of cardiac
injury and has been shown to inhibit many pathways
thought to mediate myocardial damage in diabetes
[85,90]. Additionally, PARP inhibition has been shown
to reverse diabetic endothelial dysfunction [91]. Again,
although the experimental data appear compelling, as yet
no PARP inhibitors have been developed for clinical use,
due to off-target, and perhaps on-target, drug toxicity.
PKC
PKC activity is increased in both failing [92] and diabetic
[93] hearts, and levels correlate with both ROS [94] and
PARP [85]. PKC phosphorylates a number of proteins
directlyinvolvedincardiacexcitation–contractioncoupl-
ing and therefore disturbs Ca2+ handling in cardio-
myocytes [95]. Transgenic mice overexpressing the
PKCβ2 isoform in the myocardium develop cardiac
hypertrophy, ﬁbrosis, impairment of LV function and
progressive cardiomyopathy, but these changes are
reversed using a PKCβ isoform-selective inhibitor [96].
DAG (diacylglycerol) activates PKC and is phos-
phorylated by DGK (DAG kinase), converting it into
phosphatidic acid and thereby inactivating its function
in respect to DAG [97]. It has recently been shown that
overexpression of the DGKζ isoform in both cultured
mouse cardiomyocytes and isolated perfused hearts [98],
as well as diabetic mice [99], prevents pathological
activation of PKC, attenuating cardiac hypertrophy and
ﬁbrosis and improving ventricular function. Conversely,
targeted overproduction of the PKCβ2 isoform in the
myocardium results in LVH, multifocal ﬁbrosis and
cardiomyopathy in mice [96]. CTGF (connective tissue
growthfactor),whichcontributestocardiachypertrophy
and ﬁbrosis is overexpressed in concert with PKCβ2i n
rodent models of diabetic cardiomyopathy [93]. Treat-
ment with antioxidants is capable of normalizing this
cardiachypertrophyandreducingCTGFlevels,therefore
implicating oxidative stress as a potential mediator of
PKCβ2-induced myocardial damage [100]. Inhibition
ofPKCα isalsoassociatedwithsigniﬁcantimprovements
in cardiac function in rodent models of HF [101], in con-
junction with an improved metabolic gene proﬁle in
the myocardium, as well as improved glucose utilization
and diastolic function as shown by MR spectroscopy
[102].
AGEs
Hyperglycaemia promotes formation of collagen types I
and III in the myocardium, resulting in interstitial
ﬁbrosis, which leads to LV diastolic dysfunction;
however, the mechanisms of hyperglycaemia-induced
collagen production are poorly deﬁned. The increased
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formation of AGEs secondary to hyperglycaemia, may
alter structural proteins and lead to increased myocardial
stiffness. Aminoguanidine (an inhibitor of AGE
formation and protein cross-linking) has been shown to
ameliorate changes in LV structure and function [103].
Hyperglycaemia induces oxidative stress which increases
proﬁbrogenic factors leading to interstitial ﬁbrosis, a key
alteration in diabetic cardiomyopathy. Oxidative stress
increases expression of AGE and RAGE (receptor for
AGEs) leading to an activation of NF-κB which leads to
a switch in the gene expression of cardiac MHC (myosin
heavy chain) from the α-MHC isoform to the β-MHC
isoform altering myocardial contractility [104]. DHEA
(dehydroepiandrosterone)reduces oxidativestressandin
turn has been shown to reduce tissue levels of collagen I,
collagen IV and ﬁbronectin in STZ (streptozotocin)-rats
and restore papillary muscle contractility [105]. Elevated
levels of RAGE, NF-κBa n dT G F - β1 (transforming
growthfactor-β1)mRNAinmyocardialtissueofdiabetic
rats was reduced signiﬁcantly after administration of
grape seed proanthocyanidin extract and this was associ-
ated with a decrease in the number of degenerate mito-
chondria and the preservation of ultrastructural
alterations in LV myocardium [106]. In an in vitro
study of cardiac ﬁbroblasts exposed to a high-glucose
concentration, ERK1/2 (extracellular-signal-regulated
kinase 1/2) activation led to enhanced mRNA and
protein expression of collagen types I and III, which
was ameliorated by treatment with a blocker of ERK
phosphorylation [107].
Fatty acids
Independent of the effects of hyperlipidaemia on coron-
ary artery endothelial function, diabetic hearts have
an altered metabolic phenotype, with enhanced FA
(fatty acid) utilization. A recent study in db/db mice, a
monogenicmodelofType2diabeteswithextremeobesity
and hyperglycaemia, has demonstrated increased plasma
membrane content of FA transporters [FAT/CD36 and
FABPpm (membrane associated FA-binding protein)],
leading to increased FA uptake and utilization in db/db
cardiomyocytes[105].Thishasbeenassumedtobedriven
by a range of mitochondrial mechanisms, but there was
no change in CPT-1 (carnitine palmitoyltransferase-1)
activity, malonyl CoA and UCP (uncoupling protein)-3
content suggesting that mitochondrial mechanisms do
not contribute to elevated rates of FA oxidation in db/db
hearts [105].
Dysfunctional calcium homoeostasis
Calcium is one of the principal ionic regulators in the
heart and is essential for the process of excitation–con-
tractioncouplingandthereforeintegraltonormalcardiac
function. Thus, during the cardiac action potential, the
cell membrane of the cardiomyocyte is depolarized and
calciumentersthecellthroughvoltage-dependentL-type
calcium channels in the sarcolemma. Calcium triggers the
release of further calcium ions from the SR (sarcoplasmic
reticulum) store, through the RyRs (ryanodine recept-
ors), which increase intracellular calcium and facilitate
binding of calcium to myoﬁlaments, thereby initiating
cardiac contraction. For relaxation to occur, calcium ions
must be removed from the cytosol, the majority of which
is pumped back into the SR by SERCA (sarcoplas-
mic/endoplasmic reticulum Ca2+-ATPase), while the re-
mainderisejectedoutofthecellthroughthesarcolemmal
NCX(Na2+/Ca2+ exchange),PMCA(plasma-membrane
Ca2+-ATPase)ormitochondrialcalciumuniport[106].In
bothType1andType2rodentmodelsofdiabetes,altered
expression, activity and function of all transporters
involved in excitation–contraction coupling, SERCA
[107], NCX [108], RyR [109] and PMCA [110], as well as
dysfunctional intracellular calcium signalling [111], have
been reported. These ﬁndings echo calcium mishandling
observed in HF [106]. Interestingly, candesartan, an
ARB {AT1 [AngII (angiotensin II) type 1] receptor
blocker}, has been shown to restore the contractile
deﬁcit in diabetic cardiomyopathy by stabilizing FKBP
(FK506-binding protein) 12.6 and restoring calcium
release through the RyR [112]. Depressed SERCA
activity causes inefﬁcient sequestration of calcium
in the SR, resulting in cytosolic calcium overload,
impairedrelaxationandhencediastolicdysfunction[113].
Overexpression of SERCA has been shown to improve
calcium handling [111] and protect against experimental
diabetic cardiomyopathy [107]. In a study utilizing
myocardial biopsies in seven diabetic patients with
diastolic dysfunction, myoﬁlament Ca2+ responsiveness
was found to be reduced [114]. In addition to alterations
in calcium homoeostasis, there is also reduced expression
of mRNA and protein density of key cardiac K+
channel (Kv2.1, Kv4.2, and Kv4.3) genes in LV myocytes
in experimental diabetes. This will contribute to
repolarizing K+ currents and explain the susceptibility
to arrhythmia in diabetic cardiomyopathy [115].
RAAS (renin–angiotensin–
aldosterone system)
The involvement of the RAS (renin–angiotensin system)
in HF has now begun to be deﬁned at the molecular
level in relation to HF and diabetic cardiomyopathy.
AngII exerts a direct effect on cardiomyocytes through
AT1 receptors [116]. Both diabetes and hyperglycaemia
induce functional abnormalities in ventricular myocytes,
which can be prevented by AngII blockade [117]. The
mechanistic basis for this dysfunction is not clear;
however, direct signalling via the AT1 receptor results
in increased NADPH oxidase activity and elevation of
ROS which causes oxidative damage to cardiomyocytes
and endothelial cell apoptosis [117]. In diabetes an
up-regulation of RAS occurs despite minimal changes in
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myocardial loading and increased expression of AngII
in diabetic rats has been related to cardiomyocyte
hypertrophy and apoptosis. Six weeks of STZ-diabetes
in Ren-2 (enhanced tissue renin–angiotensin expression)
rats results in impairment of both active and passive
phases of diastole with interstitial ﬁbrosis, cardiac
myocyte hypertrophy and apoptosis in conjunction with
increased TGF-β activity [118]. These ﬁndings provide
a molecular platform for the increased beneﬁts of ACE
inhibition in diabetic patients in preventing and reversing
diabetic cardiomyopathy.
AngII receptor blockers attenuate metabolic and
cellular alterations in experimental diabetes [119], reduce
ROS [120], restore SERCA activity and improve intra-
cellular Ca2+ handling in HF [121]. It is therefore not
surprising that angiotensin blockade has been shown to
provide cardiovascular protection in diabetic patients
[122]. Aldosterone antagonists also reduce cardiovas-
cular mortality in diabetic patients with HF who exhibit
elevated serum levels of collagen synthesis markers
[123], suggesting that aldosterone antagonists may pre-
vent excessive extracellular matrix turnover. As both
AngII and aldosterone induce cardiac ﬁbrosis, through
enhanced accumulation of collagen and increased ﬁbro-
blast proliferation [124], it has been suggested that
aldosterone and glucose mediate cardiac ﬁbrosis through
stimulation of myoﬁbroblast growth in patients with
a dysregulated RAAS, a pathway of cardiac pathology
which is intensiﬁed by hyperglycaemia [125].
HIF (hypoxia-inducible factor)-1 and VEGF
(vascular endothelial growth factor)
An adequate angiogenic response to hypoxia is essential
in protecting against myocardial injury during ischaemic
events.ThehypoxicstimulusismediatedlargelybyHIF-
1, a transcriptional regulator complex which controls
the expression of multiple angiogenic growth factors, of
which VEGF has received particular attention [126]. The
presenceofhypoxiaandfreeradicalsstabilizeandactivate
HIF-1α, which would otherwise be rapidly degraded
[127]. VEGF has been shown to contribute to the
development of collateral vessels [128] and is expressed
in increased quantities in cardiac myocytes and arteriolar
smooth muscle cells following MI in non-diabetic
patients [129]. However, the expressionof VEGF protein
and mRNA, as well as its receptors, are signiﬁcantly
decreased in the myocardium of both diabetic and
insulin-resistant non-diabetic rats [130]. This suggests
that, in diabetic patients, the normal molecular processes
which regulate angiogenesis may be impaired, although
therearenodirectstudiestodatetosubstantiatethis.This
may provide an explanation for the increased incidence
of post-MI cardiac failure and enhanced mortality in
diabetic patients. Interestingly, administration of TZDs
(thiazolidinediones) [131] or inhibition of NADPH
oxidase [132] results in an increase in circulating VEGF
levels in diabetic patients and animals respectively, with
restored post-ischaemic neovascularization in the latter;
implicating ROS activity once more in the pathology
of diabetic cardiomyopathy. Reductions in VEGF and
impaired angiogenic responses have also been linked
with increased levels of ET-1 in ventricles from diabetic
rodents and ET receptor antagonism increases VEGF
signalling, improving cardiac function [133].
The KKS [KLK (kallikrein)–kinin system]
There is now good evidence that the KKS has a profound
inﬂuence on cardiac and vascular function. Tissue KLK
is involved in processing vasoactive kinin peptides and
appears to have dynamic roles, with reports of both
protective and damaging effects on the cardiovascular
system [134,135]. These effects are mediated through
two distinct G-protein-coupled receptors; the BK
(bradykinin) B1R (B1-receptor) and B2R (B2-receptor).
Underbasalconditions,BKandLys-BK(kallidin)arethe
predominant kinin peptides involved in cardiovascular
homoeostasis and work principally through activation
of the B2R. The B1R has been shown to mediate
cardiac inﬂammation and may therefore contribute to
cardiovascular pathology [135].
A range of cardiovascular insults, including oxidative
stress, inﬂammatory cytokines and activation of the RAS
have been shown to regulate these receptors [136]. The
STZ-induced diabetic rat exhibits up-regulation of both
B1R and B2R [137], which may partly be explained by
activation of the RAS in diabetes [134]. Paradoxically,
KLK levels are reduced in diabetic animals [138] and
humans [139], suggesting therefore that kinin receptor
up-regulation may represent an attempted compensatory
mechanism [135].
The relationship between these cardiovascular insults
andlevelsofKLK/BKreceptorsisreciprocal.Alterations
to B2R expression by use of transgenes in experimental
models of diabetes has demonstrated protection against
diabeticcardiomyopathy.BKhasbeenshowntoimprove
insulin stimulation of GLUT4 (glucose transporter 4)
[140] via a BK B2R-induced NO pathway [141]. Follow-
ing somatic hKLK (human KLK) gene delivery to STZ-
induced diabetic rats, there is increased cardiac GLUT4
translocation, decreased cardiac glycogen synthesis and
reduced glycogen accumulation [142], suggesting that
the KKS is capable of restoring glucose utilization.
Furthermore, hKLK transgenic STZ-induced diabetic
ratsshowareducedcardiacinﬂammatoryresponse[143],
increasedlevelsofantioxidativeenzymes[144],inhibition
of collagen accumulation and restoration of SERCA2a-
associatedcalciumdisturbances[145].Functionally,these
changes are associated with subsequent improvement in
LV ﬁlling pressure/stiffness [146].
Thus there is clearly extensive cross-talk between
the KKS and the cardiovascular system. Interactive
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pathways between the KKS and the RAS, myocardial
energy metabolism, oxidative stress, inﬂammation and
calcium handling, are complex and dynamic with respect
to the BK receptor involved. Furthermore delineation
of these mechanisms may allow manipulation of this
system, potentially via blockade of the RAS, utilizing
readily available therapy (ACEIs, ARBs and renin
inhibitors) to selectively oppose the alterations which
contribute to diabetic cardiomyopathy in man.
PATHOLOGY
As a consequence of the molecular changes discussed,
characteristic structural alterations develop in the cardio-
myocytes and intramyocardial blood vessels of diabetic
individuals, contributing to the pathogenesis of dia-
betic cardiomyopathy.
Cardiomyocytes
Since the cardiomyocyte is the primary functional unit
of the myocardium, it has been the focus of studies
investigating diabetic cardiomyopathy. Light and elec-
tron microscopic ultrastructural changes of the cardio-
myocyte have been deﬁned in a range of animal models
ofdiabetes,includingthedog[147],monkey[148],rabbit
[149], mouse [150] and rat [151–154]. However, widely
varying results have been reported with regard to the
severity, onset and type of cardiomyocyte pathology.
Hence the pathology has ranged from no change [147]
to severe myocytolysis and contracture band formation
[151]. With regard to onset of alterations, some studies
have demonstrated signiﬁcant changes within 1 week
[155], whereas others only detected changes after 6 [153]
and 12 weeks [151] of experimental diabetes. Possible
explanations for these discrepancies, other than the
duration of diabetes, include the severity of hypergly-
caemia and the potential direct effect of the diabetogen
used to induce diabetes. Thompson [153] induced dia-
betes in the Sprague–Dawley rat using a single injection
of 4% alloxan monohydrate, and by light microscopy
demonstrated a progressive increase in intercellular and
perivascular matrix after 6 weeks of diabetes. However,
this abnormality was not expressed uniformly and
there was regional heterogeneity, with areas showing no
increase in matrix [153]. More detailed ultrastructural
assessment using electron microscopy demonstrated sig-
niﬁcantultrastructuralalterationsinonly15%ofthecar-
diomyocytes,whichwerecharacterizedby:(i)lossofmy-
oﬁlamentswithdisorganizationoftheremainingbundles,
(ii) areas of separation at the intercalated disk along the
fasciaeadherents,and(iii)increasedlipiddropletsandloss
of some elements of the SR and transverse tubules [153].
Alongerdurationofdiabetesleadstothedevelopmentof
more pronounced degenerative changes in larger groups
of cardiomyocytes and, at 26 weeks, approx. 60% of
the cells were affected, displaying large areas of free
cytoplasm, dispersed proteins, contracture bands and a
reduction in the frequency of SR and transverse tubules.
However, interestingly, most of the mitochondria
appeared normal with no evidence of swelling or lysis
and morphology of the cristae remained normal, despite
the presence of severe damage and disorganization of the
cytoplasm with contracture band formation. This is in
contrast with other ultrastructural studies, which have
shown swollen and fragmented mitochondria as the most
prominent ﬁnding in diabetic myocardium [149]. Indeed,
mitochondrial swelling has been observed in rats after
7 days of hyperglycaemia [155], as well as in dogs [156].
A number of other studies have reported disruption and
loss of mitochondria in more advanced stages of diabetic
cardiomyopathy [150–152].
Studies in humans are limited. Fischer et al. [157]
undertook detailed ultrastructural studies of tissue plugs
from the anterior apical segment of the heart in 145
patients undergoing CABG (coronary artery bypass
grafting). Subjects were divided into three groups:
‘overtly diabetic’, ‘chemically diabetic’ (representing
thosewithimpairedglucosetolerance)and‘euglycaemic/
non-diabetic’ patients. The study showed cardiomyocyte
hypertrophy and interstitial ﬁbrosis in all except two
samples. In addition, a spectrum of other myocardial
lesions were observed in all three groups of patients,
rangingfrommitochondrialdegenerationandfattyinﬁlt-
ration of the myoﬁbrils to contraction band formation,
perivascular and interstitial oedema and myocytolysis.
The study thus failed to detect speciﬁc alterations in the
cardiomyocytes of diabetic patients, as all changes were
also present in non-diabetic patients [157]. The one
ultrastructural alteration which distinguished diabetic
from non-diabetic patients was capillary basement
membrane thickening, which will be discussed below.
However, it is important to note that the criteria used
to group the patients was not precise and overlap
between the groups could have resulted from ambiguous
terminology, dividing patients into ‘overtly diabetic’ and
‘chemically diabetic’.
With regard to the size of cardiomyocytes, contrasting
studies in diabetic patients and animal models demon-
strate both cardiomyocyte hypertrophy and atrophy.
Cardiomyocyte apoptosis has been demonstrated in
the diabetic myocardium of animal models [158], as
well as in humans [159]. In STZ-induced diabetic rats
[160], TUNEL (terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling) detected 3-OH
strand breaks resulting from DNA breakdown. The nuc-
lear marker DAPI (4 ,6-diamidino-2-phenylindole) was
used to counterstain DNA and cells deﬁned as apoptotic
if the nuclei showed a sharply demarcated morphology
and were labelled by the TUNEL assay, were increased
3.3-fold in diabetic rats, although the overall incidence
of this abnormality was very low [160]. However, it
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Table 1 Summary of the major structural changes in experimental and human diabetic cardiomyopathy
↑ indicates increase; ↓ indicates decrease; = indicates no difference. BB, BioBreeding; ZDF, Zucker diabetic fatty.
Diabetes type Model Cardiac mass
Cardiomyocyte
diameter
Cardiomyocyte
loss Mitochondria SR Apoptosis
Intramyocardial
lipid Fibrosis
Type 1 diabetes STZ rat =[151] or
↓[166,201]
↓[166,201] ↑[151] ↑[151,155,201] ↑[151,155] ↑[158] ↑[151,155] =[201] or
↑[166]
Alloxan rat =[153] ↑[153] =[153] ↑[153] ↑[153]
BB Wistar rat ↓[152] ↑[152] ↑[152] ↑[152] ↑[152] ↑[152]
Type 2 diabetes KK mice ↑[163] ↑[163] ↑[163] ↑[163]
ZDF rat =but after
insulin↑[202]
↑[202] ↑[203] ↑[202]
ob/ob Mice ↑[150,204] ↑[204] or
↓[150]
↑[150] ↑[150] =[204] or
↑[150]
=[204]
Type 1 and 2
diabetes
Humans ↑[205,206] ↑[207,208] or
↓[209]
=?[157] =?[157] =?[157] ↑[159] =?[157] =[157] or
↑[208]
is important to note that this method is not speciﬁc
for detecting those cells which do eventually undergo
apoptosis and a more accurate means to detect actual
cardiomyocyteapoptosisisbyelectronmicroscopy,butis
rarelyemployed.Astudyofhumandiabeticmyocardium
has shown an 85-fold increase in cardiomyocyte apop-
tosis [159]. Such apoptotic myocyte loss may be one of
themechanismscontributingtothepoorprognosisindia-
betic patients after MI [161]. Several reports have shown
thatinhibitionofmyocardialcelldeathbyantioxidantsor
inhibitorsofapoptosis-speciﬁcsignallingpathways,leads
to signiﬁcant prevention of diabetic cardiomyopathy
[162]. Table 1 summarizes all of the structural changes
which have been reported in diabetic cardiomyopathy.
Myocardial microvessels
Although most structural studies of the myocardial
vasculature have concentrated on coronary arteries and
intramural arterioles, few studies have assessed myocar-
dial capillary structure in either clinical or experimental
diabetes. Some reports show signiﬁcant ultrastructural
changes in cardiomyocytes, in the absence of any vascu-
lar change [152,163], whereas others report vascular
changes as the only speciﬁc myocardial alteration in
the diabetic heart [157]. The aforementioned study by
Thompson [153] was unable to detect any structural
abnormalities in the myocardial capillaries during the
ﬁrst 6 weeks of diabetes. At 26 weeks, however, a 3-fold
increase in thickening of the endothelial cytoplasm, with
endothelial cell hypertrophy and cytoplasmic bridging
led to complete obstruction of the lumen. The capillary
basementmembraneshowedmoderate,irregularthicken-
ing with occasional areas of duplication, with all changes
distributedfocallythroughoutthepapillarymuscle[153].
Thickening of the capillary basement membrane has
been reported in mice [150], rats [164] and humans
[157,165]. Thompson [166] further quantiﬁed the effect
of diabetes on different components of the myocardial
microvasculature in rats, by demonstrating a decrease
in mean capillary diameter by 11% after 12 weeks and
22% after 26 weeks of diabetes. Moreover, stereological
analysis showed a signiﬁcant progressive decrease in
capillarydensity,whichafter26 weeksofdiabetesreached
77% of the value seen in non-diabetic age-matched
control rats [166]. Ultrastructural signs of angiogenesis
have also been reported and are characterized by
alterations in endothelial and pericyte shape [164]. A
study of human diabetic myocardium [157] found two
characteristic abnormalities in myocardial capillaries:
endothelial swelling and/or degeneration and thickening
of the capillary basement membrane (Figure 2). This is
the pathological hallmark of diabetic microangiopathy
and occurred in an uneven, patchy, segmental manner
[157].Diabeticmyocardialcapillarymicroangiopathyhas
also been shown by others [167,168]. Table 2 summarizes
the microvascular alterations seen in models of diabetic
cardiomyopathy.
TREATMENT
Sulfonylureas
Of the relatively little published data on the use of
sulfonylureas in diabetic HF, two studies have reported
conﬂicting ﬁndings in terms of outcome [169,170].
A recent meta-analysis has indicated that these drugs
are not associated with an increase in cardiovascular
events [171,172]. Clearly, further studies are needed to
determine the beneﬁts and possible harm of these drugs
in diabetic patients with HF.
Metformin
Metformin was previously contraindicated in patients
with HF in the U.S. due to the theoretical risk of lactic
acidosis; its use is still strongly cautioned. Evidence
to support the use of metformin in HF comes from
three cohort studies in which metformin therapy was
comparedwithotherOHAs(oralhypoglycaemicagents)
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Table 2 Summary of the major microvascular changes in
experimental and human diabetic cardiomyopathy
BB, BioBreeding; ZDF, Zucker diabetic fatty.
Diabetes type Model Microvascular changes
Type 1 diabetes STZ rat Decreased capillary diameter and
density [166]
Narrow capillary lumen with
endothelial swelling [164]
Basement membrane thickening [201]
Alloxan rat Decreased capillary lumen [153]
Endothelial swelling [153]
Basement membrane thickening [153]
BB Wistar rat No changes [152]
Type 2 diabetes KK mice No changes [163]
ZDF Perivascular ﬁbrosis [202]
ob/ob Mice Basement membrane thickening [150]
Type 1 and 2 diabetes Humans Basement membrane thickening
[157,165]
and insulin respectively [171]. Metformin treatment was
associated with a reduction in all-cause mortality and
all-cause hospital admissions. In addition to its modest
insulin-sensitizingproperties,metforminhasbeenshown
in an animal model to inhibit cardiac hypertrophy [173].
TZDs
The TZDs [PPARγ (peroxisome-proliferator-activ-
ated receptor γ) receptor agonists] are primarily insulin-
sensitizing agents, but in addition to their antihyper-
glycaemic action, these drugs also exert beneﬁcial
effects on the myocardium, vascular endothelium, lipid
proﬁle and BP with additive anti-inﬂammatory and
proﬁbrinolytic effects [174]. They have been shown in
both animal and human studies to improve myocardial
metabolism and glucose handling [175]. In a 6 month
double-blind, randomized, multicentre study comparing
pioglitazone with glyburide in patients with Type 2
diabetes, systolic dysfunction and NYHA (New York
Heart Association) functional class II/III HF, although
Figure 2 Electronmicrograph of a myocardial capillary from a diabetic patient, demonstrating luminal occlusion with
basement membrane thickening
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pioglitazone was associated with a higher incidence
of hospitalization for HF there was no increase in
cardiovascular mortality or worsening cardiac function
(by echocardiography) [176].
Thus the increased risk of HF is due to ﬂuid retention
via increased renal retention of sodium and subsequent
plasma volume expansion and there is no evidence to
suggest that TZDs may be harmful to the myocardium.
In contrast, animal and experimental studies have
demonstratedfavourableeffectsonthemyocardiumsuch
as reduced cardiac hypertrophy and improved systolic
and diastolic function [177]. Results from clinical trials
assessing TZD use and cardiac function however, is
limited by both number and validity. Hence, the use of
TZDs in HF is restricted to those in NYHA functional
class I–II [178]. Two recent meta-analyses of seven and
19 randomized controlled trials of TZDs (pioglitazone
or rosiglitazone), reported an increase in the risk of HF
in diabetic and pre-diabetic subjects [RR of 1.72 and
HR (hazard ratio) 1.41 respectively] [179,180], but there
was no increase in the risk of cardiovascular mortality
in these studies. Rosiglitazone has been associated with
an increased risk of MI [177]. In the PROactive study,
although pioglitazone was associated with a signiﬁcant
increase in serious HF (10.8% compared with 7.5% over
3 years, P<0.0001), there was no increase in mortality or
cardiovasculareventscomparedwithplacebo[181].Thus
the overall cardiovascular beneﬁts derived from pioglit-
azone are thought to outweigh such risks [182]. In the
RECORD (Rosaglitazone Evaluated for Cardiovascular
OutcomesandRegulationofglycemiainDiabetes)study,
rosiglitazone-treatedpatientshadaslightlyincreasedrisk
ofincidentHF(1.7comparedwith0.8%,P=0.006)after
a mean treatment period of 3.8 years [183].
Insulin
Insulin use in diabetic patients has also been associated
with an increased risk of HF and death [171]. Cohort
studies in diabetic populations with HF have yielded
conﬂicting results. In the CHARM (Candesartan in
Heart Failure: Assessment of Reduction in Mortality and
Morbidity)study,theriskofdeathwasgreaterindiabetic
patients treated with insulin compared with those not
treated with insulin [184]. These ﬁndings contrast with
those of UKPDS which did not report an increase in
mortality with insulin use [171].
GLP-1 (glucagon-like peptide-1) analogues
GLP-1 is an ‘incretin’ hormone which stimulates post-
prandial insulin secretion and improves insulin sensitiv-
ity.GLP-1analoguesexerttheircardiovascularbeneﬁtin-
directlybyinducingweightlossandimprovingglycaemic
proﬁle and endothelial function [185]. There is some
promisingdatafromatrialofGLP-1analoguesinpatients
following successful coronary intervention for acute MI
whereby the treated group demonstrated a signiﬁcantly
greater improvement in LVEF (29+ −2% compared with
39+ −2%, P<0.01) with concomitant improvements in
global and regional wall motion [186]. The same group
conducted a trial of GLP-1 analogues in patients with
advanced HF and reported signiﬁcant improvements in
LVEF, ˙ Vo2max (maximal oxygen consumption), 6 min
walk distance and standardized QOL (quality-of-life)
score [187]. Clearly, long-term data are required for this
classofdrugstodeterminetheirefﬁcacyandsafetyinHF.
DPP-4 (dipeptidyl peptidase-4) inhibitors
The DPP-4 inhibitors or gliptins are a group of drugs
which increase incretin levels by inhibiting the enzyme
DPP-4. Of note, DPP-4 is expressed on the endothelium
of myocardial venules and paradoxically has been shown
tobereducedinexperimentaldiabetes[164].Theseagents
are relatively new and, as for the GLP-1 analogues, one
may predict a long-term beneﬁt on cardiovascular and
all-cause mortality. Long-term morbidity and mortality
trials are currently underway, but it will be several years
before the data is reported.
Metabolic modulators
Theseagents,previouslyusedasanti-anginals,addressthe
imbalance in myocyte energy efﬁciency by facilitating
the switch from NEFA (non-esteriﬁed FA; ‘free FA’)
to glucose metabolism. Trimetazidine, one such agent
currently available in Europe, inhibits an enzyme
involved in the β-oxidation of NEFAs and has been
shown to improve LVEF, NYHA functional class and
QOLinpatientswithHF[188].Similarly,perhexilinehas
demonstratedsubstantialimprovementsinLVEF, ˙ Vo2max
and QOL, but is associated with a risk of hepatotoxicity
and peripheral neuropathy [189]. Ranolazine, is another
drug with potential as a metabolic modulator [190]. It
reduces intracellular Na+ and diastolic Ca2+ overload,
thus improving diastolic function, but it has been
associated with prolongation of the QT interval.
The RAAS
The role of the RAAS in the pathogenesis of diabetic
cardiomyopathy has been described above and forms
the rationale for treatment with ACEIs and ARBs
in diabetic cardiomyopathy. Both ACE inhibition and
treatment with ARBs reduce total and cardiovascular
mortality in diabetic patients [191,192]. In addition,
there was a reduction in cardiovascular events in large
studies such as RENAAL [45], HOPE (Heart Outcomes
Prevention Evaluation) [193] and IDNT (Irbesartan
Diabetic Nephropathy Trial) [194], the effect being
more pronounced in diabetic compared with non-
diabetic patients. Furthermore, in the CHARM study
[184], candesartan was associated with a 40% reduction
in the diagnosis of new onset diabetes and similarly, in
the SOLVD study, treatment with enalapril reduced the
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incidence of diabetes compared with placebo [23]. A
meta-analysis of the major HF trials found an RR of 0.84
for death in diabetic patients treated with ACEIs [195].
The CHARM and Val-HeFT [196] studies also demon-
strated mortality and morbidity beneﬁts with ARBs
which were similar in diabetic and non-diabetic patients.
β-Blockers
β-Blockers are now well-established in the treatment of
HF. Concerns in diabetic patients with regard to the in-
creased risk of hypoglycaemia, dyslipidaemia and insulin
resistance has meant that diabetic patients with HF are
less likely to be discharged from hospital on a β-blocker
than their non-diabetic counterparts [197]. However, the
GEMINI (Clinical Utility of Amlodipine/Atorvastatin
to Improve Concomitant Cardiovascular Risk Factors of
HypertensionandDyslipidemia)studycomparedtheuse
ofcarvedilolwithmetoprololinpatientsalreadyreceiving
ACEIs or ARBs [198] and demonstrated that carvedilol
improved insulin resistance and had no effect on HbA1c,
whereas metoprolol worsened HbA1c and did not im-
prove insulin resistance. Although to date there has not
been a study of β-blockers in diabetic patients with HF,
up to a quarter of patients in the major β-blocker trials in
HF were diabetic [199,200]. Subgroup analysis of these
trials demonstrated signiﬁcant mortality and morbidity
beneﬁts in diabetic patients. In a meta-analysis of these
trials, the overall RR of mortality in diabetic patients was
0.84 compared with 0.72 in non-diabetic patients.
CONCLUSIONS
Considerable progress has been made to unravel the
mechanistic basis for the increased frequency of HF
in diabetic individuals. Functional consequences such
as diastolic and then systolic dysfunction and failure
correlate with glycaemic control. These functional alter-
ations are preceded by a variety of structural, molecular
and cellular changes, many of which are present in
asymptomatic diabetic individuals and experimental
models of diabetes. Moreover, alterations to myocardial
and vascular integrity appear to initiate during a
pre-diabetic stage. Although the aetiology of diabetic
cardiomyopathy is complex and multifactorial, we have
begun mapping a molecular, structural and functional
basis for this condition and the debate regarding its
existenceasadistinctclinicalentityisatanend.Atpresent
however, translational studies are lacking and it remains
under-diagnosed and inadequately treated. Although hy-
perglycaemiaappearstodrivethepathogenesisofdiabetic
cardiomyopathy, intensive glycaemic control in diabetic
patients has not translated into meaningful morbidity
and mortality beneﬁts, indeed recent results suggest the
possibility of worsening outcomes. Novel diagnostic
techniques to identify patients earlier, together with the
development of more targeted therapeutic strategies ex-
ploiting recent experimental data, may lead to improved
outcome in patients with diabetic cardiomyopathy.
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